NIPBL

Across TCGA pan-cancer cohorts, NIPBL mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of NIPBL’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where NIPBL mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types NIPBL is over-expressed in tumor.

LSCC, HNSC, and LUAD are the cancer types where NIPBL tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NIPBL mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	All	+0.444	<.001	8	view →
HNSC	Male	All	+0.340	<.001	8	view →
LUAD	Male	All	+0.208	<.001	8	view →
COAD	Male	II,III,IV	+0.169	<.001	8	view →
CCRCC	Male	All	+0.158	<.001	7	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

NIPBL–LSCC

Open the LSCC breakdown →